esophageal cancer
Conditions
Interventions
A group, intravenous indwelling catheters (Insight, 20 G, 30 mm) manufactured by Becton Dickinson Company
B group, intravenous indwelling catheter (Insight, 22 G, 32 mm) manufactured by Japan Becton D
Sponsors
Kochi Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Among patients who underwent esophageal resection, cases in which blood glucose control is performed. 2. A performance status of 0-2 accord ing to the Eastern Cooperative Oncol ogy Group (ECOG) scale. 3. An age of 20 years and over. 4. Patients who are considered to survive for more than 3 months from the registration. 5. Vital organ functions are preserved within 14 days prior to entry. 6. Sufficient oral intake. 7. All patients gave written informed consent.
Exclusion criteria
Exclusion criteria: 1. Obvious infection or inflammation. 2. Serious cardiovascular diseases. 3. Serious concurrent disease such as intestinal palsy, small bowel obstraction, uncontrolable diabetes mellitus, renal failure, liver cirrhosis, and so on. 4. Massive ascites beyond the pelvic cavity or pleural effusion. 5. Women who are pregnant or hope to become pregnant during the study period. Men who wish their partner to become pregnant. 6. Patients judged inappropriate for the study by their physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of defective blood sampling | — |
Secondary
| Measure | Time frame |
|---|---|
| Problem solving method required when blood sampling failure. Time taken to recover from blood sampling failure. Percentage of blood sampling failures time during use of artificial pancreas . | — |
Countries
Japan
Contacts
Public ContactHiroyuki Kitagawa
Kochi Medical School Department of Surgery
Outcome results
None listed